Hypoparathyroidism
Drug research and approvals for hypoparathyroidism: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 36 studies of hypoparathyroidism are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, FDA has 3 approved and 6 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 36
- Trials authorized in Canada: 8
- FDA orphan approvals: 3
- EU medicines: 1
- German Hypoparathyroidism RegistryNCT07857460 · Not reported · University Hospital Augsburg · starts Jul 6, 2021
- Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic HypoparathyroidismNCT07805356 · Phase 3 · Calcilytix Therapeutics, Inc., a BridgeBio company · starts Aug 31, 2026
- A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term HypoparathyroidismNCT07706764 · Phase 3 · Ascendis Pharma A/S · starts Apr 22, 2026
- A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With HypoparathyroidismNCT07699471 · Phase 3 · MBX Biosciences · starts Aug 26, 2026
- The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based…NCT07643896 · Not reported · BillionToOne Inc. · starts Jan 10, 2026
- NIRAF-Guided Parathyroid Identification During ThyroidectomyNCT07617584 · Not applicable · Ss. Cyril and Methodius University of Skopje · starts Sep 1, 2026
- Risk Factors for Hypoparathyroidism Following ThyroidectomyNCT07582562 · Not reported · Tartu University Hospital · starts Oct 13, 2025
- Calcium Replacement Therapy in Postoperative HypoparathyroidismNCT07577570 · Not applicable · Tartu University Hospital · starts Nov 18, 2025
- Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal…NCT07493096 · Not reported · Healing Hope International · starts Mar 1, 2026
Approved 4
- Parathyroid hormoneParathyroid hormone receptor agonist
- CalcitriolVitamin D receptor agonist
- ErgocalciferolVitamin D receptor agonist
- PalopegteriparatideParathyroid hormone receptor agonist
Phase 3 1
- Teriparatide acetateParathyroid hormone receptor agonist
Phase 2 1
Phase 1 or earlier 3
How its trials ended
100 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 21 whose ending is known, 62% met their primary endpoint, 5% missed it and 33% stopped early.
- Completed, result not reported3838%
- Ongoing2727%
- Status unknown1414%
- Met its primary endpoint1313%
- Stopped: other or unclear33%
- Stopped: sponsor or business decision22%
- Missed its primary endpoint11%
- Stopped: enrollment or feasibility11%
- Stopped: funding11%
| Aug 11, 2026 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension investigating efficacy, safety, and…Encaleret | Calcilytix Therapeutics Inc | Pending |
| May 11, 2023 | A phase 3 multi center, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of eneboparatide (AZP3601), a parathyroid…Eneboparatide (AZP-3601) | AstraZeneca Pharmaceuticals | Ongoing |
| Dec 1, 2020 | Pathway trial: a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group trial, with an open-label extension, investigating the…Palopegteriparatide (transcon pth) | Ascendis Pharma | Closed |
| Apr 20, 2020 | A randomized, double-blind, multiple ascending oral dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PCO371 in…PCO371 | Chugai Pharmaceutical | Ongoing |
| May 9, 2019 | Path forward: a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group trial with an open-label extension, investigating the…Palopegteriparatide (transcon pth) | Ascendis Pharma | Closed |
| Dec 20, 2018 | A randomized, double-blind, placebo-controlled, adaptive study to evaluate symptom improvement and metabolic control among adult subjects with symptomatic…RHPTH(1-84) (recombinant human parathyroid hormone) | Takeda Pharmaceuticals USA | Closed |
| Mar 1, 2018 | An open-label study investigating the safety and efficacy of rhpth (1-84) in subjects with hypoparathyroidismRhpth (1-84) | Takeda Pharmaceuticals USA | Pending |
| Dec 22, 2017 | Open-label, randomized, crossover study to assess the pk and pd profiles of once-daily and twice-daily dose regimens of recombinant human parathyroid hormone…RHPTH(1-84) | Takeda Pharmaceuticals USA | Ongoing |
| Aug 9, 2024 | YorvipathTreatment of hypoparathyroidism in adults | Ascendis Pharma Bone Diseases A/S | Approved |
| Jan 23, 2015 | NatparaAn adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Dec 23, 1987 | ParatharDiagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due… | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Approved |
| Jul 25, 2022 | Fatty acylated parathyroid (prodrug) hormone agonistTreatment of hypoparathyroidism | MBX Biosciences | Designated |
| May 25, 2022 | PTH(1-34)-Cys(succinimido-PEG-vitamin D) amide (human)…Treatment of hypoparathyroidism | Extend Biosciences Inc. | Designated |
| Dec 14, 2020 | H-Ala-Val-Ala-Glu-Ile-Gln-Leu-Met-His-Gln-Arg-Ala-Lys-Trp-Il…Treatment of Hypoparathyroidism | Amolyt Pharma SAS (formerly Alize Pharma III SAS) | Designated |
| Dec 15, 2014 | Non-peptide small molecule orally available agonist of the…Treatment of hypoparathyroidism | Chugai Pharma USA, LLC | Designated |
| Apr 18, 2014 | TeriparatideTreatment of hypoparathyroidism | Entera Bio, Ltd. | Designated |
| Jan 26, 2001 | Synthetic Human Parathyroid Hormone 1-34Treatment of hypoparathyroidism | Rare Disease Therapeutics, Inc. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 17, 2023 | YorvipathPalopegteriparatide · orphan | Ascendis Pharma Bone Diseases A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA